Polku Therapeutics
Develops small-molecule therapies for neurodegenerative diseases by targeting tau aggregation and neuroinflammation
Highlights
- Young companyFounded 2024
- New on EvolcAdded 2026-10-28
About Polku Therapeutics
Polku Therapeutics develops small molecules that target the PREP–PP2A axis to promote clearance of toxic protein aggregates, reduce tau phosphorylation and dampen inflammation. Its pipeline includes programs for frontotemporal dementia, progressive supranuclear palsy, Alzheimer’s and Parkinson’s diseases.
The company is based in Helsinki, Finland, and was founded in 2024. It reports a pre-seed funding round and is seeking life science investors and biopharma partners for preclinical R&D collaborations.
Product: Small-molecule drug candidates targeting PREP–PP2A biology for neurodegenerative diseases.
Jobs at Polku Therapeutics
More biotech & pharma companies
PrecisionPhage
Phage genome bioinformatics software, lab services and a phage library for AMR and phage therapy researchYoung companyNew on EvolcPrimoceler
Hermetic glass packaging and laser bonding for active implantable device electronics, from prototype to series productionNew on EvolcProbiont
Develops organ-on-a-chip solutions to test cancer immunotherapy efficacy for personalized treatment assessmentNew on EvolcPuro Analytics
EDNA biodiversity monitoring for organisations: species detection, fish and forest surveys, lab analysis and reportsYoung companyNew on EvolcRappta Therapeutics
Develops first-in-class anti-cancer molecular glues that reactivate the tumor suppressor PP2A, for oncology drug developmentNew on EvolcReagena
Diagnostic tests and laboratory reagents for clinical, biotechnology, pharmaceutical and research organizationsNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Next.js
- React
- Vercel